Tumor Cell Proportion
Tumor Cell Proportion - Related Videos
01:20
Sample Proportion and Population Proportion
0 Views •
2023
Collecting samples or responses from an entire population takes significant time and effort, so a researcher collects responses from only a sample of that population. Suppose a study needs to collect information about a specific mobile application. After sample collection, the researcher analyzes the data and discovers that most individuals in the sample use that specific mobile application. The sample proportion measures the number of individuals in a sample who either use or don't use the...
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
0 Views •
2025
This protocol describes the in vivo reprogramming of mouse cancer cells into type 1 dendritic-like cells within the tumor microenvironment through enforced expression of the transcription factors PU.1, IRF8, and BATF3.
10:15
Isolation and Culture Expansion of Tumor-specific Endothelial Cells
0 Views •
Cited by 20 •
2015
We report a reliable method to isolate and culture primary tumor-specific endothelial cells from genetically engineered mouse models.
04:17
Long-term Orthotopic Transplantation of Tumor Cells into Zebrafish Embryos: An Efficient Method to Deliver Tumor Cells into the Fourth Ventricle of Zebrafish Embryos for Long-term Analysis of Tumor Cell Behavior
0 Views •
2025
This video demonstrates the orthotopic transplantation of zebrafish brain tumor cells into the fourth ventricle of an immunocompetent zebrafish embryo. This procedure allows for the long-term study of tumor cell invasion and behavior.
04:28
Lung Tumor Cell Recruitment Assay
0 Views •
2019
This manuscript describes a method to quantify tumor cell accumulation in the lungs in an animal model of tumor metastasis.
FAQs
The reported value depends partly on what region is being assessed. A pathologist may estimate tumor cell proportion across the whole specimen or within the specific area chosen for analysis, and those measurements can differ when malignant cells are unevenly distributed. Stating the assessment scope therefore helps readers interpret the result and compare it with downstream testing.
Normal stromal, inflammatory, and necrotic components reduce the relative representation of malignant cells in a tissue section. This matters because molecular assays depend on tumor-derived DNA or RNA: a specimen with too little tumor material may not provide a reliable result. Proportion assessment consequently links microscopic composition with the analytical suitability of the sample.
Evaluation relies on stained sections, where malignant cells are distinguished from surrounding tissue elements rather than viewed separately from the specimen’s architecture. Stromal and inflammatory cells, along with necrotic areas, are considered during interpretation. Recognizing these components helps prevent a substantial tissue fragment from being mistaken for a sample rich in tumor cells.
A basic assessment begins with review of a stained tissue section, followed by identification of malignant cells and separation from normal stromal, inflammatory, and necrotic components. The pathologist then estimates the percentage for either the entire specimen or a selected analysis area. Recording the relevant scope keeps the result interpretable for later clinical or research use.
Before molecular testing, tumor cell proportion helps determine whether a biopsy contains enough tumor-derived DNA or RNA for dependable analysis. The estimate does not replace the molecular assay; instead, it provides quality-related context for judging whether the tested material adequately represents the lesion. This is especially relevant when results are used for biomarker interpretation.
In clinical and translational medicine, the measurement contributes to more than specimen acceptance. It supports assessment of biopsy adequacy, tumor grading, treatment planning, biomarker interpretation, and evaluation of sample quality. Its usefulness comes from connecting microscopic evidence of tumor representation with decisions about how confidently a specimen can support diagnosis, research, or clinical testing.